

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**MicroPort Scientific Corporation**

**微創醫療科學有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 00853)**

### **POSITIVE PROFIT ALERT**

This announcement is made by MicroPort Scientific Corporation (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap.571, Law of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform holders of the Company’s shares and securities and potential investors that, based on information currently available to the Board, the Group is expected to record a net profit of not less than USD4 million for the six months ended 30 June 2016 as compared with a net loss of USD2.59 million recorded for the six months ended 30 June 2015. The expected increase in the unaudited net profit for the six months ended 30 June 2016 is principally attributable to:

- (1) a significant growth in revenue from the cardiovascular and endovascular segments in the PRC market, and in particular, a significant revenue growth of our third generation coronary stent product Firehawk® Drug Eluting Stent; and
- (2) a significant amount of foreign exchange gain from our RMB-denominated debts of overseas subsidiaries resulted from the depreciation of RMB.

The Company is still in the process of preparing and completing the interim results of the Group for the six months ended 30 June 2016 (the “**2016 Interim Results**”). The information contained in this announcement is a preliminary assessment made by the Board based on the latest management accounts of the Group which have not been audited or reviewed by the independent auditors of the Company. Holders of the Company’s shares and securities and potential investors are advised to read the Company’s announcement of the 2016 Interim Results carefully, which is expected to be published before the end of August 2016.

**Holders of the Company's shares and securities and potential investors are advised to exercise caution when dealing in the shares and securities of the Company.**

By Order of the Board  
**MicroPort Scientific Corporation**  
**Dr. Zhaohua Chang**  
*Chairman*

Shanghai, the People's Republic of China, 27 July 2016

*As at the date of this announcement, the executive director is Dr. Zhaohua Chang; the non-executive directors are Mr. Norihiro Ashida, Mr. Hiroshi Shirafuji, Ms. Weiwei Chen and Ms. Janine Junyuan Feng; and the independent non-executive directors are Mr. Jonathan H. Chou and Dr. Guoen Liu.*

*\* for identification purpose only*